An American company Novavax is currently working on the development of the COVID-19 vaccine. Novavax reported that it has started with a Phase 2b clinical trial in South Africa to assess the effectiveness of a Covid-19 vaccine in a volunteer.
Dr Shabir Madhi, a professor of Vaccinology at the Witswatersrand University, will be leading the clinical trials that are partly supported by a $15 million donation from the Bill & Melinda Gates Foundation, the Novavax said in a realesed statement on Monday 17th of August 2020.
The American company, Novavax also mentioned that the vacinne trial will be made up of two units.
The first batch will examine the success rate, safety and immunogenicity in approximately 2,665 healthy South African adults.
The second batch is meant to assess the safety and immunogenicity in close to 240 medically stable and HIV-positive adults.
This will allow the assessment of the trail vaccine to be tested over a diverse, representative study group population.
Novavax said it expects that, if the trail COVID-19 vaccine is officially approved in South Africa, their Covid-19 vaccine will be disbursed to South Africa in the long run through a partnership with the Serum Institute of India.
Content created and supplied by: LifestyleZA (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More